Interferon regulatory factors (IRFs) are essential in the innate immune response and other physiological processes. Activation of these proteins in the cytoplasm is triggered by phosphorylation of serine and threonine residues in a C-terminal autoinhibitory region, which stimulates dimerization, transport into the nucleus, assembly with the coactivator CBP/p300 and initiation of transcription. The crystal structure of the transactivation domain of pseudophosphorylated human IRF5 strikingly reveals a dimer in which the bulk of intersubunit interactions involve a highly extended C-terminal region. The corresponding region has previously been shown to block CBP/p300 binding to unphosphorylated IRF3. Mutation of key interface residues supports the observed dimer as the physiologically activated state of IRF5 and IRF3. Thus, phosphorylation is likely to activate IRF5 and other family members by triggering conformational rearrangements that switch the C-terminal segment from an autoinihibitory to a dimerization role.
Interferon regulatory factors (IRFs) are essential in the innate immune response and other physiological processes. Activation of these proteins in the cytoplasm is triggered by phosphorylation of serine and threonine residues in a C-terminal autoinhibitory region, which stimulates dimerization, transport into the nucleus, assembly with the coactivator CBP/p300 and initiation of transcription. The crystal structure of the transactivation domain of pseudophosphorylated human IRF5 strikingly reveals a dimer in which the bulk of intersubunit interactions involve a highly extended C-terminal region. The corresponding region has previously been shown to block CBP/p300 binding to unphosphorylated IRF3. Mutation of key interface residues supports the observed dimer as the physiologically activated state of IRF5 and IRF3. Thus, phosphorylation is likely to activate IRF5 and other family members by triggering conformational rearrangements that switch the C-terminal segment from an autoinihibitory to a dimerization role.
Our survival depends on molecular defense mechanisms that include both tumor suppression and immunogenic responses to pathogens. Breakdown of these mechanisms can lead to cancer and infection, whereas hyperactivity can result in autoimmune disease. The interferon (IFN) regulatory factors (IRFs) are key transcription factors involved in such defense mechanisms, having been directly implicated in the innate immune response and other physiological roles [1] [2] [3] .
IRF5 is a particularly interesting IRF family member with various activities, including activation of type I IFN genes 4, 5 , inflammatory cytokines 6 and tumor suppressors 7, 8 . Expression of IRF5 has been detected primarily in B cells and dendritic cells, and is stimulated by type I IFN, viral expression and the tumor suppressor p53 (refs. 9-12) . Although type I IFN responses are beneficial to the host, inflammatory cytokines that are stimulated by IRF5 can be a major contributor to the morbidity and mortality associated with viral pathogenesis. In particular, mutations in IRF5 are associated with pathogenesis of autoimmune diseases including systemic lupus erythematosis 13, 14 , Sjögren's syndrome 15 , multiple sclerosis 16 and inflammatory bowel disease 17 . Understanding how IRF5 activity is controlled at the molecular level, therefore, is potentially important clinically, as therapeutic agents that enhance activity could combat virus infection or tumor growth 18 , whereas agents that attenuate activity could be used to minimize harmful inflammatory responses. The physiological importance of IRF5 makes it an important prototype for investigating regulation of IRF proteins.
IRF proteins, including IRF5, comprise two major domains, an N-terminal DNA binding domain (DBD) and a C-terminal domain that is largely responsible for activation. The well-conserved DBD (B120 amino acids) recognizes positive regulatory domain DNA sequences in the IFNb enhancer region, as well as IFN-stimulated response elements (ISREs) in IFN-induced genes. Details of the interaction of various IRF DBDs with DNA and their participation with other factors in transcriptional activation of the IFNb gene have been elucidated by several crystallographic analyses [19] [20] [21] [22] . The C-terminal portions regulate the transcriptional activity of the IRFs. IRF3 through IRF9 possess a C-terminal IRF-association domain (IAD), which is responsible for homo-and heteromeric interactions among the IRFs as well as interaction with transcriptional comodulators. The transactivation functions of the IADs of IRF3, IRF4, IRF5 and IRF7 have been shown to be suppressed by autoinhibitory structures flanking the IAD 10, 23, 24 .
The most extensively studied member of this family is IRF3. IRF3 is constitutively expressed in all cell types, remaining in the cytosol in a latent, autoinhibited form until activated. Upon viral infection, IRF3 is phosphorylated by two serine-threonine kinases, TBK1 and IKKe 25, 26 . Phosphorylation induces IRF3 to homo-or heterodimerize, translocate into the nucleus and assemble with CREB binding protein (CBP) or the closely related p300, allowing promoter binding and activation of the IFNb gene [27] [28] [29] . Crystal structures of the transactivation domain of IRF3 (refs. 30,31) revealed the conformation of an autoinhibitory region near the C terminus that contains the key phosphorylation sites. A subsequent crystal structure of CBP in complex with IRF3 lacking the C-terminal phosphorylation region demonstrated that CBP binds to the surface masked by the autoinhibitory region in the monomeric structure 32 . Thus, these structures strongly suggest that phosphorylation triggers an unfolding of a C-terminal autoinhibitory region, but they do not explain how such structural rearrangements are coupled to dimerization or why dimerization favors binding of CBP/p300.
To provide a structural basis for IRF5 function and to understand how the phosphorylation of IRF proteins activates dimerization and binding to CBP/p300, we have determined the crystal structure of the transactivation domain of human IRF5 with a phosphomimetic mutation that enhances dimer formation. The C-terminal autoinhibitory region, including key phosphorylation sites, adopts a highly extended conformation that mediates homodimerization. In the process, the CBP/p300 binding surface is largely unmasked in the dimer, providing a clear structural link between phosphorylation, dimerization and CBP/p300 binding.
RESULTS

IRF5 phosphomimetic mutants
We investigated the self-association and CBP interactions of purified IRF5 (residues 222-467) and potential phosphomimetic mutants (S421D, S425D, S427D, S430D, S436D and S457D) by size-exclusion chromatography, analytical sedimentation velocity and isothermal titration calorimetry (ITC). (At least nine different isoforms of IRF5 have been shown to result from differential splicing 11 , leading to variations in residue numbering. Our studies used variant 4.) ITC experiments with CBP (residues 2067-2112) showed that S421D and S457D weakened interactions with CBP, but the other four mutations increased affinity by factors of 1.7-fold to 2.9-fold relative to the wild type ( Table 1 and Supplementary Fig. 1 online) . These results are consistent with previous experiments that showed mutation of these four serine-to-aspartate substitutions rendered IRF5 constitutively active 33 . Of these mutants, S430D showed the strongest affinity with CBP. Size-exclusion chromatography showed that mixing of CBP with both IRF5 222-467 and IRF5 222-467 S430D resulted in a shift in elution volume that is consistent with oligomerization ( Supplementary Fig. 2 online). Sedimentation velocity experiments (Supplementary Methods online) confirmed the conclusion from gel-exclusion chromatography that IRF5 222-467 and IRF5 222-467 S430D form IRF5 2 CBP 2 assemblies in the presence of CBP ( Supplementary Fig. 2 ). These results strongly suggest that CBP binding and IRF5 dimerization are coupled events. Furthermore, sedimentation experiments show that IRF5 222-467 S430D assembles into stable homodimers in the absence of CBP (Supplementary Figs. 2b and 3 online). Because IRF5 222-467 S430D forms dimers, representative of activated IRF5, structural studies were initiated on this form.
Crystallographic analysis of IRF5 S430D
We determined the crystal structure of the transactivation domain of IRF5 222-467 S430D (hereafter referred to as IRF5) to 2.0-Å resolution using single heavy atom isomorphous replacement to solve the phase problem. The crystals contain one polypeptide chain per asymmetric unit. An atomic model has been refined to a conventional R-factor of 0.205 and an R free of 0.242.
Tertiary structure of IRF5
The tertiary structure of the IAD of IRF5 is similar to that of IRF3 (Fig. 1) . Ca coordinates for core structures of IRF5 and IRF3 can be aligned with an r.m.s. deviation of 1.4 Å for 138 (out of 185) IAD residues. (Residues used in this alignment are shown in cyan in Fig. 1) . However, the C-terminal regions (IRF5 residues 423-457, magenta) show markedly different conformations. The C-terminal region of the IRF3 monomer forms an autoinhibitory structure whose position masks a hydrophobic surface for binding CBP/p300 (refs. 31,32) . In IRF5, this region is in an extended conformation, which strongly contributes to dimerization (see below) and largely exposes the CBP/p300 binding surface. A short N-terminal helix remains packed against the CBP/p300 binding surface; in the cocrystal structure of truncated IRF3 with CBP 32 , a similar short N-terminal helix becomes displaced upon binding CBP (Fig. 1c) . Other structural differences are present in the lengths of helix 4, helix 5 and the conformation of the connecting polypeptide. Given the structural similarities of the IAD of IRF5 and IRF3, many of these differences are likely to represent structural changes that occur upon activation and dimerization. Phosphorylation sites (yellow balls) evidently trigger switching between these markedly different conformations.
IRF5 S430D Dimer
The homodimer of IRF5 probably represents the activated form and shows an extensive intermolecular surface with favorable interactions (Fig. 2a) . The dimer assembles from two IRF5 monomers that are related by a crystallographic two-fold axis. Intradimer contacts involve helix 4, helix 5 and the extended connecting polypeptide from one subunit packing against a second subunit at the surface formed by helix 2 and several interstrand loops. A total surface area of 5,800 Å 2 is buried in the dimeric interface, with the C-terminal autoinhibitory and dimerization region (residues 423-457) participating in 74% of this buried surface. The buried surface area in the IRF5 dimer is substantially larger than the 2,200Å 2 surface area buried by the autoinhibitory region of monomeric IRF3 and the 1,800Å 2 buried in the IRF3-CBP complex 32 . These observations strongly implicate the C-terminal region as having a key role in activation.
The dimeric interface involves a mixture of hydrophobic and hydrophilic contacts (Fig. 2b) . Contributing centrally to the hydrophobic dimeric interactions are Ile431, Leu433 and Ile435, which lie in the extended region of polypeptide between helix 4 and helix 5. These residues pack against a hydrophobic surface formed by residues Tyr303¢, Leu307¢ and Val310¢ in helix 2 and Leu403¢ from loop L5 (primes designate partner subunit). IRF5 residues Ile431, Leu433 and Ile435 are homologous to IRF3 residues Val391, Leu393 and Ile395, respectively, which pack against the CBP/p300 binding surface in monomeric IRF3 (ref. 31 ). These three positions are largely occupied by isoleucine, leucine and valine residues among the IRF family members, as are many of the acceptor residues ( Supplementary  Fig. 4 online). Isoleucine, leucine and valine residues have been shown in folding studies to be particularly suitable for forming stable hydrophobic clusters 34 . Thus, packing of these branched hydrophobic amino acids is likely to contribute to the overall stability of the dimeric IRF5 interface.
Hydrophilic interactions provide specificity to the dimer and dominate the contact involving the region near the beginning of helix 5 (Fig. 2b) . Key hydrophilic interactions involve Asp442 (helix 5) with Arg353¢ (loop 3), Lys449 (helix 5) with Asp309¢ and Asp312¢ (helix 2), Lys441 (helix 5) with Glu354¢ (loop L3) and Ser436 with Arg328¢ (strand b6) ( Fig. 2b and Supplementary Fig. 5 online). This constellation of hydrophilic interactions contributes to the complementarity of the dimeric interface.
One exception to the hydrophilic interface interactions of helix 5 is Val445 (Fig. 2b) . Val445 is within 4.5 Å of three hydrophobic residues in the partner subunit: Leu269, Leu278 and Phe279. These residues lie in loop L1, which is substantially longer in IRF5 than in several other IRF family members ( Supplementary Fig. 4 ). Although these interactions are not tight, the exclusion of water may contribute to greater stability of the IRF5 dimer relative to those of other IRF family members.
Helix-capping hydrogen bonds 35 involving carbonyl oxygen atoms at the C termini of helices 3 and 4 ( Fig. 2c ) also contribute to the dimeric interface. Helix 3 is capped by a likely hydrogen bond with Lys401¢. The last turn of helix 4 in dimeric IRF5 is unwound relative to that of monomeric IRF3 and seems to be stabilized by two helixcapping hydrogen bonds involving Arg247¢ and Gln373 (Fig. 2c) . These hydrogen bonds may have a central role in the formation of the dimer by favoring unwinding of the last turn of helix 4, thus contributing to the extended polypeptide between helices 4 and 5 that participates in other key dimeric interactions.
Role of potential phosphorylated serine residues ITC experiments (Table 1) implicate Ser425, Ser427, Ser430 and Ser436 as important phosphorylation sites. The IRF5 crystal structure shows that phosphorylated Ser425, Ser427 and Ser430 will not participate in dimeric contacts; rather, phosphorylation of these residues is likely to contribute to activation by triggering the unfolding of the autoinhibitory structure in the monomer. In contrast, Ser436 is within hydrogen-bonding distance of Arg328¢ (Fig. 2d) ; Arg328 is one of the few absolutely conserved residues in human IRF3 through IRF9 ( Supplementary Fig. 4 ). This interaction is likely to be strengthened upon phosphorylation of Ser436. The homologous residue in IRF3, Ser396, is important for phosphorylation-induced IRF3 activation 28, 36, 37 , with several studies suggesting that this site 2 residue is important for releasing autoinhibition but that phosphorylation of a site 1 residue (Ser385/Ser386) is required for dimerization 38, 39 . Our structure suggests a more direct role for Ser436 in dimerization of IRF5. S436D showed a similar increase in affinity of IRF5 for binding CBP as did S430D (Table 1) , despite a potential role of phosphorylated Ser436 in stabilization of the activated dimer. That S436D is not more stabilizing for CBP binding suggests that the phosphomimetic may not accurately mimic the stabilizing interactions of phosphoserine at position 436 in the dimeric contact as a result of stereochemical and charge differences between aspartate and phosphoserine. Thus, phosphorylation of Ser425, Ser427 and Ser430 is likely to contribute to activation primarily by destabilizing the autoinhibitory conformation of the C-terminal region, but the phosphorylation of Ser436 may additionally contribute directly to stabilization of the activated dimer.
IRF5 mutants of key dimeric interface residues
We investigated the relevance of the crystallographically observed dimer by site-directed mutagenesis of key interface residues. We selected sites for mutation on the basis of their involvement in the dimeric interface but also their likelihood of being exposed to solvent in the monomeric state. Mutants chosen to disrupt the hydrophobic packing interactions were L307D, V310D and L403D, and those designed to disrupt ionic and hydrophilic interactions included D442R, R353D and R328E (Fig. 2b) .
Dimerization of IRF5 mutants was tested using size-exclusion chromatography with CBP. Each mutant was constructed in IRF5 222-467 S430D to investigate whether the mutations were capable of disrupting dimer formation, even in the presence of this dimerfavoring phosphomimetic. We also constructed the double mutant R328E S436D. Mutants V310D, R353D, D442R and R338E (both in the context of S430D and S436D) were investigated by size-exclusion chromatography. (L307D S430D and L403D S430D double mutants did not express well in Escherichia coli.) None of these mutants forms a dimer even in the presence of CBP (Fig. 3a) . SDS-PAGE on concentrated fractions of the IRF5 V310D S430D peak run with CBP showed no evidence of CBP (data not shown), suggesting that mutants that are unable to dimerize are also unable to bind CBP. These results indicate that the dimer observed in the crystal structure is formed in solution.
To test the physiological relevance of this dimer, we engineered dimer-destabilizing mutations in a full-length IRF5 vector and tested them using an IRF5 reporter assay in HEK293 cells. Upon activation by the TLR adaptor MyD88, IRF5 translocates to the nucleus, where it binds to and activates transcription of the IFNb reporter gene. Activation of IRF5 was disrupted with mutants of both hydrophobic and hydrophilic interface residues. Single mutants R338D, R353D, L307D and L403D, double mutants L307D V310D and D442R R353D, and a triple mutant L307D V310D L403D showed severely compromised activation of IRF5 that was comparable to the results using an empty vector (Fig. 3b) . Although still defective, the single-site mutants V310D and D442R showed only a partial signal reduction. We verified equivalent expression of all mutants by western blot analysis of the same lysates as those analyzed for luciferase activity (Fig. 3b) . Thus, the crystallographically observed dimer is physiologically relevant, as its disruption inhibits activation of IRF5.
IRF3 dimeric activation
Comparison of the autoinhibited IRF3 and dimeric IRF5 structures suggests that, for the most part, IRF3 should be able to attain a similar dimer to that found for IRF5. The only region where such dimer formation would induce unfavorable contacts is in Loop L5. The observed L5 structural differences could reflect distinctions between IRF3 and IRF5 or dimerization-induced conformational transitions. Comparison of crystal structures of IRF3 in the autoinhibited monomer with the IRF3-CBP complex shows conformational changes of L5 that occur as a result of crystal contacts 31, 32 . Notably, loop L5 in the IRF3-CBP crystal structure is more similar to that of the IRF5 dimer than it is to that in the autoinhibited monomer ( Supplementary  Fig. 6 online) . Apparently, loop L5 has intrinsic flexibility that allows its rearrangement upon dimerization. A conserved glycine (Gly390 in IRF5) near the beginning of loop L5 ( Supplementary Fig. 4 ) may contribute to this plasticity and allow IRF3 to assemble into a similar dimer to that observed here for IRF5.
To test directly whether IRF3 forms an activated dimer similar to that of IRF5, we mutated the two interface residues that are absolutely conserved in family members IRF3 through IRF9. In the IRF5 dimer, Arg328¢ contacts Ser436, and Leu403 contributes to hydrophobic interactions. Both R285E (homologous with Arg328 in IRF5) and L362D (homologous with Leu403 in IRF5) were constructed in the background of the S386D S396D double mutant, which dimerizes in the presence of CBP 37 . In both cases, size-exclusion chromatography indicates that these triple mutants elute as monomers in the presence of CBP (Fig. 3c) , strongly supporting the hypothesis that IRF3 forms a similar dimer to that observed in the IRF5 crystal structure.
To test the physiological relevance of this IRF3 dimer, we engineered the same mutations in a full-length IRF3 vector for use with assays in HEK293 cells and fibroblasts from IRF3-deficient mice. Transfection of HEK293 cells with wild-type IRF3 alone dose-dependently increased IFNb reporter-gene activity, an effect that was further enhanced upon infection with Newcastle Disease Virus (NDV) infection, as expected. In contrast, the R285E mutant was much less active either when transfected alone or in the presence of NDV infection (Fig. 3d) . The L362D mutant was completely defective in driving the IFNb reporter alone and did not enhance the NDV response above baseline levels. Western blot analysis of the highest dose of transfected IRF3 in each case revealed equivalent expression levels (Fig. 3d, inset) . Because HEK293 cells express IRF3 endogenously, we also tested the ability of these mutants to reconstitute NDV-induced IFNb reportergene activation in fibroblasts lacking functional IRF3. These fibroblasts failed to induce IFNb reporter-gene activity in response to NDV infection, but, when the cells were transfected with wild-type IRF3, NDV did induce IFNb reporter-gene activation. However, neither the R285D nor the L362D mutants could reconstitute signaling in these cells (Fig. 3e) . These results pinpoint Arg285 as a key residue in the inhibition of virus-induced dimerization observed previously in the triple mutant (R285A H288A H290A) 31 .Taken together, these data support the idea that activation of IRF3 involves formation of a similar dimer to that of IRF5.
DISCUSSION
The first direct, high-resolution structural information of an activated IRF reveals a dramatic phosphorylation-dependent structural rearrangement of the C-terminal region that triggers dimerization of IRF5. Thus, this work provides a structural basis for understanding how phosphorylation activates IRF family members.
Our mutagenesis studies support the idea that the observed dimer represents the activated state of both IRF5 and IRF3. Published data on IRF3 mutants further supports the conclusion that IRF3 dimerizes similarly to IRF5. A triple mutation of loop L6 residues, in which Val391, Leu393 and Ile395 (homologous with IRF5 residues Ile431, Leu433 and Ile435, respectively) were simultaneously mutated to arginine, was previously constructed 31 to disrupt autoinhibitory contacts. As hypothesized, this triple mutant abolished the virusdependent activation, but, unexpectedly, also interfered with IRF3 oligomerization. Such an interference with oligomerization of IRF3 is precisely the expected effect if the IRF3 dimer is similar to the IRF5 dimer, with these three residues in the interface. Additional published IRF3 mutants are also consistent with similar dimer formation to that of IRF5. These include double mutations (R211A R213A and K360A R361A) and triple mutations (R255A R262A H263A and R285A H288A H290A) that have been shown to inhibit virus-induced dimerization of IRF3 (refs. 30,31) . In each mutant protein, one or more of the mutated residues is homologous with a residue in the IRF5 interface. Taken together, both the published data and the results presented here strongly support the crystallographically observed IRF5 dimer as representing the activated state of both IRF5 and IRF3.
The dramatic structural transitions observed for IRF5 seem to be a signature of the IRF family that is not shared with the evolutionarily related 30, 31 Smad proteins involved in TGF-b signaling. In both IRF and Smad proteins, phosphorylation of serine and threonine residues in the C-terminal region triggers oligomerization. In Smad proteins, phosphorylation of serine residues in the C-terminal SSXS motif drives homo-and heterotrimerization because of the direct binding of these phosphorylated serines in the trimer interface 40 . In contrast, the phosphorylation sites in IRFs are more than 20 residues from the C terminus. As a result, phosphorylation triggers much larger structural changes. Such structural changes can expose binding sites for other proteins, including CBP/p300, that contribute to signaling. In addition, the structural complexity of phosphorylation-mediated signaling in IRFs suggests differential roles for individual sites: Ser425, Ser427 and Ser430 act primarily to destabilize the autoinhibited form, whereas Ser436 contributes to dimeric stability. These considerations suggest that conformational changes in IRF signaling may permit a complex, differentiated biological response to particular site-specific phosphorylations.
Following phosphorylation, IRF5 is translocated into the nucleus. Two potential nuclear localization signals (NLS) have been identified 10 . In contrast to IRF3 and IRF7, IRF5 can be detected in the nucleus of uninfected cells, which could result from the presence of two NLSs 9, 10 . Also, unlike other IRFs, one putative NLS has been identified in the C-terminal transactivation domain. NLS signals are normally found on unstructured surface loops, which permit binding to importin-a (karyopherin-a) [41] [42] [43] . The residues identified in the C-terminal domain as an NLS (398-PREKKLI-404) are located in loop L5, which is intimately involved in the dimeric interface and may therefore mask them from binding importin-a. Thus, the mutagenesis results on the putative NLS residues 10 may need to be re-evaluated, as such mutations are likely to disrupt dimerization, which, in and of itself, could alter nuclear localization.
Dimerization of the IRF5 transactivation domain initiates the process leading to binding of full-length IRF5 to DNA. Although no crystal structure of the N-terminal DBD of IRF5 with DNA is available, structures of the well-conserved DBDs from several other IRF family members with DNA are available [19] [20] [21] [22] . The human IFNb enhancer comprises binding sites for up to four IRF DBDs, as well as activators NFkB and ATF-2/Jun. Pairs of DBDs that could reasonably be part of an IRF dimer have C-terminal Ca atoms separated by 42-49 Å 21,22 . These distances are consistent with the subunit arrangement for the IRF5 transactivation domain observed here, in which the N-terminal Ca atoms of the two IRF5 subunits are 59 Å apart. Thus, the B75-residue linker region between the N-terminal and C-terminal domains is not required to substantially alter the spacing between subunits for optimal DNA binding. However, this region must permit differences in the orientation of the two DBDs upon DNA binding, because the two-fold symmetry relating the two C-terminal domains in the dimer is not present in the tandem bound DBDs (Fig. 4) . As a result, dimerization of the transactivation domain brings the DBDs into only an approximate position for binding DNA. IRF5 and IRF3 show substantially different responses to phosphorylation mimetics, with changes in affinity between CBP and IRF3 that are much more dramatic than those reported here for IRF5. In the case of IRF3, single phosphomimetic mutations increased affinity for CBP up to 19-fold, and double mutations increased affinity up to 120-fold 37 . In contrast, the largest change in affinity for binding CBP with IRF5 was only 2.9-fold ( Table 1 ). These differences are consistent with earlier studies indicating that, unlike IRF3 and IRF7, an unphosphorylated autoinhibitory domain cannot completely inhibit activation of IRF5 (ref. 10). Thus, the phosphorylation-dependent switch between autoinhibition and activation is more finely tuned in IRF5 than in IRF3.
The marked differences in sensitivity to activation between IRF3 and IRF5 are likely to represent different functional requirements that reflect distinct physiological roles of different IRFs. For instance, IRF3 is constitutively expressed in all cells, acting as a molecular sentry for viral infection. As such, it must be strongly autoinhibited and activated only in response to a clear signal. The C-terminal autoinhibitory and dimerization region has a central role in activation. This region shows low sequence similarity ( Supplementary Fig. 4 ) among IRFs, including no absolutely conserved residues among IRF3 through IRF8. For IRF3, the large number of hydrophobic residues in the IAD probably contribute to its lower basal activity compared with IRF7 and IRF5 (ref. 31 ). An additional factor is the stability of the activated dimer. The IRF5 structure highlights several hydrophobic and ionic interactions that stabilize the dimer and may contribute to its greater basal activity. For instance, the ionic interaction between Arg353¢ and Asp442 seems likely to be absent in IRF3 and IRF7, as the equivalent residues are Lys313 and Ser402 in IRF3 and Arg398 and Tyr488 in IRF7. In IRF3, the K313A mutant does not show a defect in virus-induced dimer formation 31 (the only reported nondefective IRF3 mutation of a residue homologous to an IRF5 dimeric interface residue). The absence of dimer stabilization by Lys313 may contribute to the tight autoinhibitory control of IRF3. Additionally, the hydrophobic surface formed by residues in the L1 loop that interacts with a portion of helix 5¢ in IRF5 is absent in IRF3 and likely to be absent in IRF7 ( Supplementary Fig. 4 ), which could also weaken IRF3 and IRF7 dimers relative to the IRF5 dimer. Therefore, the sensitivity of a given IRF family member is likely to be controlled through the balance between intramolecular autoinhibitory interactions and intermolecular dimeric interactions.
In conclusion, the structure of dimeric IRF5 reveals that phosphorylation-induced activation of IRF5 and other IRF family members involves a dramatic structural transition of the C-terminal autoinhibitory/dimerization region. Phosphorylation triggers unfolding of this region, allowing an extended conformation that binds to another IRF5 monomer. In doing so, the CBP binding site is exposed, providing a clear structural link between phosphorylation, dimerization and CBP/p300 binding (Fig. 4) , key steps in transcriptional activation of IFNb and associated genes.
METHODS
Protein expression. The cDNA fragment of human IRF5 (residues 222-467; variant 4 in ref. 11) was generated by PCR and subcloned into the pGEX-6p-1 vector (Amersham). The IRF5 protein was expressed in E. coli strain HB101 with a glutathione S-transferase (GST) tag, extracted by glutathione Sepharose, and released by PreScission Protease (Phamacia Biotech). Eluted protein was dialyzed in DEAE buffer (20 mM Tris, pH 7.3, 10 mM NaCl, 0.1 mM EDTA, 1 mM DTT and 1 mM PMSF). Protein was purified using a DEAE-Sepharose column and eluted by a gradient of 10-300 mM NaCl. Site-directed mutants of IRF5 215-477 were generated using the QuikChange kit (Strategene) and confirmed by sequencing. The DBDs bind to DNA in a tandem, rather than a two-fold, arrangement requiring that the two-fold symmetry of the IAD does not extend to the DBDs when bound to DNA.
The cDNA fragment of CBP (residues 2067-2112) was generated by PCR and subcloned into the pGEX-6p-1 vector (Amersham). The GST-CBP fusion protein was expressed with a GST tag and extracted by glutathione Sepharose. Eluted proteins were dialyzed in DEAE buffer. Protein was purified using an SP-Sepharose column equilibrated with DEAE buffer and eluted by a gradient of 10-300 mM NaCl.
Size-exclusion chromatography and isothermal titration calorimetry measurements. To assess the level of assembly and CBP binding to IRF5, complexes were analyzed by size-exclusion chromatography on a Superdex 200 HR column using the Ä kta Explorer 10 fast protein liquid chromatography (FPLC) system (Superdex 200, 10/30, Pharmacia Biotech) at 23 1C in FPLC buffer (20 mM HEPES, pH 7.3, 0.1 mM EDTA, 100 mM NaCl and 1 mM DTT). IRF5 (or mutants) and mixtures of IRF5 (or mutants) with a three-fold molar excess of CBP were incubated overnight at 4 1C. Before loading onto the column, the samples were incubated in 1 mM Tris-(2-carboxyethyl)phosphine (TCEP) for 60 min at room temperature. FPLC was operated and data were analyzed with UNICORN software (Amersham Biosciences). The column was calibrated with blue dextran (to determine void volume) and molecular weight standards ranging from 43 kDa to 440 kDa and run at a flow rate of 0.5 ml min -1 .
To measure the binding of purified CBP 2067-2112 with IRF5 and its mutants, we used ITC 44 with a VP-ITC calorimeter (MicroCal). All samples were dialyzed against ITC buffer (20 mM HEPES, pH 7.3, 100 mM NaCl, 0.1 mM EDTA and 1 mM TCEP) and degassed before titration. Experiments were performed at 25 1C. Isothermal interactions between proteins were measured by titrating over 55 injections using 1.4 ml of 40 mM protein against 300 ml of 400 mM CBP. The heats of dilution were measured by titrating CBP into ITC buffer; these values were subtracted for data analysis. Data were analyzed with Origin 7.0 software (MicroCal), using a single-site binding model. DH, DS and K a values were experimentally determined, and DG was calculated from the equation, DG ¼ ÀRT ln K a .
Crystallization and crystal structure determination. Crystallization was carried out with hanging drops of 2 ml protein, mixed with an equal volume of precipitating solution, that were allowed to equilibrate with the precipitating solution at 23 1C by vapor diffusion. The crystals used for structure determination were grown using a 16 mg ml -1 protein solution that was equilibrated with 100 mM imidazole, pH 7.0, and 0.5-2.0% (w/v) PEG 6000.
Diffraction data were collected to 2.0-Å resolution from a native crystal at the National Synchrotron Light Source (NSLS) beamline X29. The crystal was flash frozen in the cold nitrogen stream following a brief soak in a cryoprotectent solution of 100 mM imidazole, pH 7.0, 1% (w/v) PEG 6000, 15% (v/v) ethylene glycol and 15% (v/v) glycerol. A heavy-atom derivative was obtained by soaking these crystals in 2 mM mercury-[(o-carboxyphenyl)thio] ethyl sodium salt for 5 d. Diffraction data from this derivative were collected on our R-AXIS IV image plate system (Rigaku). Diffraction data were processed using HKL2000, DENZO and SCALEPACK 45 .
Heavy-atom analysis, phase improvement and initial model building were carried out with the SOLVE/RESOLVE package 46 . Four heavy-atom sites were found and refined, resulting in a figure of merit of 0.48-3.2-Å resolution. Density modification was applied with RESOLVE incorporating all the data to 2.0-Å resolution, resulting in a figure of merit of 0.51. (This analysis clearly showed space group P3 1 21 rather than its enantiamorph P3 2 21 was correct.) Automatic model building by RESOLVE succeeded in building 179 residues into the structure. This represented 76% of the 236 residues in the final refined structure. Iterative cycles of refinement, with CNS 47 and REFMAC5 (ref. 48) (including TLS refinement 49 ) , and model building in O 50 and COOT 51 were carried out to complete the structure ( Table 2) . Residues 458-467 were not visible in the electron density maps and are not included in the refined model. All residues in the model have conformations that are either in the most favored region (91.2%) or additional allowed region (8.8%) of a Ramachandran plot. Figures 2 and 3 and Supplementary Figures 3 and 4 were generated with PyMOL (http://pymol.sourceforge.net).
Lucerferase reporter assays. The IFNb luciferase, full-length IRF5-v4-Flag, IRF3-Flag and MyD88 were used as previously described 4 . pGL4-TK Renilla luciferase was from Promega. For HEK293 assays, 2 Â 10 4 cells per well in 96-well plates were transfected with 40 ng of the IFNb luciferase reporter gene and 40 ng of the thymidine kinase Renilla-luciferase reporter gene, together with the indicated doses of either wild-type or mutant IRFs using Genejuice (Novagen). Where indicated, cells were also transfected with MyD88 expression plasmids. Transfected cells were either untreated or, where indicated, were infected with NDV (LaSota Strain, 8 HAU ml -1 ) for 16 h. IRF3-deficient fibroblasts were prepared from IRF3-deficient mice originally obtained from T. Taniguchi (University of Tokyo). IRF3-deficient fibroblasts, 10 4 cells per well in 24-well plates were transfected with 250 ng of IFNb-luciferase, 250 ng TK-Renilla reporter and 20 ng, 40 ng or 80 ng of the IRF constructs. After 8 h, cells were either uninfected (mock) or infected with NDV for 16 h. In all cases, luciferase activity was measured as previously described 4 and data were normalized according to the manufacturer recommendations (Promega). 
